Half-year report · Q2
6095.TEDINET S100VQUM
Period2024-10-01 → 2025-03-31
Filed2025-05-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.3bn | 2024-10-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥14.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥7.9bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Operating income | ¥629m | 2024-10-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥836m | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥831m | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥654m | 2024-10-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥550m | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2023-10-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥199m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥427m | 2024-10-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥213m | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥14.8bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥15.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥14.9bn | at 2024-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.0bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥6.1bn | at 2024-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥9.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥9.5bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥8.7bn | at 2024-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.2bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.4bn | at 2023-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥149m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥807m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥93m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥47m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥360m | 2024-10-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥378m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥19.65 | 2024-10-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.26 | 2023-10-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥9.18 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 66.1% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | revenue external | 2024-10-01 → 2025-03-31 | ¥123m |
| Otherother segments | segment profit | 2024-10-01 → 2025-03-31 | −¥6m |
| Reconciling Itemsreconciling | revenue | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-10-01 → 2025-03-31 | −¥74m |
| Reconciling Itemsreconciling | segment profit | 2024-10-01 → 2025-03-31 | −¥683m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥2m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥964m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥4.1bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥72m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2024-10-01 → 2025-03-31 | ¥393m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2024-10-01 → 2025-03-31 | ¥166m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2024-10-01 → 2025-03-31 | −¥38m |
| —segment total | revenue | 2024-10-01 → 2025-03-31 | ¥6.3bn |
| —segment total | revenue external | 2024-10-01 → 2025-03-31 | ¥6.2bn |
| —segment total | revenue intersegment | 2024-10-01 → 2025-03-31 | ¥74m |
| —segment total | segment profit | 2024-10-01 → 2025-03-31 | ¥1.3bn |
| Otherother segments | revenue | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue external | 2023-10-01 → 2024-03-31 | ¥1.2bn |
| Otherother segments | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥419,000 |
| Otherother segments | segment profit | 2023-10-01 → 2024-03-31 | ¥159m |
| Reconciling Itemsreconciling | revenue | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-10-01 → 2024-03-31 | −¥23m |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-03-31 | −¥679m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥2.0bn |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥13m |
| jpcrp040300-q2r_E30650-000Doctor Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥967m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥4.4bn |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥10m |
| jpcrp040300-q2r_E30650-000Marketing Supportreportable segment | segment profit | 2023-10-01 → 2024-03-31 | ¥520m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | revenue external | 2023-10-01 → 2024-03-31 | ¥234m |
| jpcrp040300-q2r_E30650-000Medical Institution Support Platformreportable segment | segment profit | 2023-10-01 → 2024-03-31 | −¥131m |
| —segment total | revenue | 2023-10-01 → 2024-03-31 | ¥6.7bn |
| —segment total | revenue external | 2023-10-01 → 2024-03-31 | ¥6.6bn |
| —segment total | revenue intersegment | 2023-10-01 → 2024-03-31 | ¥23m |
| —segment total | segment profit | 2023-10-01 → 2024-03-31 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Retirement benefit expenses sga | Prior1YTDDuration | 5920000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 5353000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E30650-000DoctorPlatformReportableSegmentMember | 2007884000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E30650-000MarketingSupportReportableSegmentMember | 4388111000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E30650-000MedicalInstitutionSupportPlatformReportableSegmentMember | 233633000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 6629628000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OtherReportableSegmentsMember | 1220592000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 7850221000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E30650-000DoctorPlatformReportableSegmentMember | 12865000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E30650-000MarketingSupportReportableSegmentMember | 10160000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E30650-000MedicalInstitutionSupportPlatformReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 23025000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OtherReportableSegmentsMember | 419000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -23445000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E30650-000DoctorPlatformReportableSegmentMember | 2020749000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E30650-000MarketingSupportReportableSegmentMember | 4398271000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E30650-000MedicalInstitutionSupportPlatformReportableSegmentMember | 233633000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 6652654000 | JPY |
| Net sales | Prior1YTDDuration_OtherReportableSegmentsMember | 1221012000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -23445000 | JPY |
| Net sales | Prior1YTDDuration | 7850221000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E30650-000DoctorPlatformReportableSegmentMember | 967486000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E30650-000MarketingSupportReportableSegmentMember | 519516000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E30650-000MedicalInstitutionSupportPlatformReportableSegmentMember | -130974000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 1356028000 | JPY |
| Operating income | Prior1YTDDuration_OtherReportableSegmentsMember | 159420000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -679453000 | JPY |
| Operating income | Prior1YTDDuration | 835994000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E30650-000DoctorPlatformReportableSegmentMember | 1953208000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E30650-000MarketingSupportReportableSegmentMember | 4070198000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E30650-000MedicalInstitutionSupportPlatformReportableSegmentMember | 165747000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 6189154000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OtherReportableSegmentsMember | 123214000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 6312369000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E30650-000DoctorPlatformReportableSegmentMember | 2300000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E30650-000MarketingSupportReportableSegmentMember | 72058000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E30650-000MedicalInstitutionSupportPlatformReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 74358000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OtherReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -74358000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E30650-000DoctorPlatformReportableSegmentMember | 1955508000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E30650-000MarketingSupportReportableSegmentMember | 4142256000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E30650-000MedicalInstitutionSupportPlatformReportableSegmentMember | 165747000 | JPY |
| Net sales | CurrentYTDDuration_ReportableSegmentsMember | 6263513000 | JPY |
| Net sales | CurrentYTDDuration_OtherReportableSegmentsMember | 123214000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -74358000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |